Inhibikase Therapeutics (IKT) Prices $110M Private Placement to Advance IkT-001Pro Oct 9, 2024 09:19AM
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension Oct 9, 2024 09:18AM
Inhibikase Therapeutics (IKT) Prices 1.67M Share and Warrant Offering at $1.68/sh May 20, 2024 08:01AM
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million May 20, 2024 08:01AM
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference Mar 23, 2022 08:00AM